Abstract: In various embodiments targeted interferon constructs are provided. In certain embodiments the constructs comprise a full-length immunoglobulin or a camelid antibody attached to an interferon gamma (IFN?) where said immunoglobulin or camelid antibody is an antibody that binds to a tumor associated antigen; a first interferon gamma (IFN?) is attached to a first constant heavy region 3 (CH3) of the immunoglobulin or camelid antibody by a first proteolysis resistant peptide linker; a second interferon gamma is attached to a second constant heavy region 3 (CH3) of the immunoglobulin or camelid antibody by a second proteolysis resistant peptide linker; and the first proteolysis resistant linker and the second proteolysis linker have a length and flexibility that permits said first interferon gamma and said second interferon gamma to dimerize.

Abstract: In various embodiments methods are provided that involve the use of antibody-interferon (Ab-IFN) fusion proteins to boost the cancer-fighting capacity of adoptive T cell therapies (ACT), including any T cells that are manipulated and grown outside the body, then returned to the patient with the goal of having the infused T cells home to sites of tumor and destroy the cancer in an immunologic attack. Illustrative, but non-limiting, adoptive T cell therapies include chimeric antigen receptor (CAR) T cells, tumor-infiltrating lymphocytes (TILs), virus-specific T cells, and T cell receptor transgenic T cells.